Liquidia Corporation Provides Update on New Drug Application for YUTREPIA™ (treprostinil) inhalation powderGlobeNewsWire • 01/25/24
Wall Street Analysts Believe Liquidia Technologies, Inc. (LQDA) Could Rally 29.94%: Here's is How to TradeZacks Investment Research • 01/10/24
What Makes Liquidia Technologies, Inc. (LQDA) a Strong Momentum Stock: Buy Now?Zacks Investment Research • 01/09/24
Liquidia Corporation Files Response to United Therapeutics Lawsuit and Files CounterclaimsGlobeNewsWire • 01/08/24
Liquidia Corporation to Present at 42nd Annual J.P. Morgan Healthcare ConferenceGlobeNewsWire • 01/02/24
U.S. Federal Circuit Affirms Earlier PTAB Decision to Invalidate All Claims of United Therapeutics Patent No. 10,716,793 (‘793 Patent)GlobeNewsWire • 12/20/23
Liquidia Corporation Reports Third Quarter 2023 Financial Results and Provides Corporate UpdateGlobeNewsWire • 11/07/23
Liquidia Corporation to Report Third Quarter 2023 Financial Results on November 7, 2023GlobeNewsWire • 10/31/23
United Therapeutics Corporation Files Lawsuit Alleging Infringement of Tyvaso Patent Already Found to Be Invalid by U.S. Patent OfficeGlobeNewsWire • 09/06/23
Liquidia Technologies, Inc. (LQDA) Reports Q2 Loss, Tops Revenue EstimatesZacks Investment Research • 08/10/23
Liquidia Corporation Reports Second Quarter 2023 Financial Results and Provides Corporate UpdateGlobeNewsWire • 08/10/23
Liquidia Corporation to Report Second Quarter 2023 Financial Results on August 10, 2023GlobeNewsWire • 08/03/23
Liquidia Submits Amendment to Add PH-ILD Indication to Tentatively Approved NDA for YUTREPIA™ (treprostinil) Inhalation PowderGlobeNewsWire • 07/27/23
Liquidia Corporation and Pharmosa Biopharm Announce Collaboration for Sustained-Release Inhaled Treprostinil Product in North AmericaGlobeNewsWire • 06/28/23